Zegfrovy Sunvozertinib drug, a fairly new clinical agent, is generating significant attention within the cancer community. Its mechanism of action mostly involves specific inhibition of epithelial growth factor receptor (EGFR) tyrosine activity, showing potential in treating various tumor kinds. Initial clinical investigations have demonstrated enc